Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201303 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02201303 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 40 participants.
The verdict
NCT02201303, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children \<2 years and healthy adults. The study will evaluate differences in neutrophil activation between RSV-infected children \<2 years and healthy adults with escalating concentrations of Chemokine (C-X-C motif) Ligand 1 (CXCL1) and danirixin to determine if RSV-infected children and adult neutrophils are similarly activated by CXCL1 and inhibited by danirixin. This study will guide dose prediction to inhibit specific percentages of neutrophils in future pediatric RSV-infection studies. This single-center, in vitro study will consist of 2 parts. Approximately 24 subjects will be enrolled, including 12 healthy adults and 12 RSV-infected children \<2 years.
Interventions
- DRUG Danirixin
- OTHER CXCL1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-01-13 |
| Est. Completion | 2015-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201303
The ClinicalTrials.gov registry entry for NCT02201303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Danirixin is the first listed.
NCT02201303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201303 about?
NCT02201303 is a clinical study titled "Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression". This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children \<2 years and healthy adults. The study will evaluate differences in neutrophil activation between RSV-infected childr...
What is the current status of trial NCT02201303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-01-13. Estimated completion is 2015-07-02.
What interventions are being tested in trial NCT02201303?
The interventions under investigation include: Danirixin (DRUG), CXCL1 (OTHER).
Who is sponsoring clinical trial NCT02201303?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.